Summary
With the increased politicization of drug pricing, the Administration is reportedly contemplating regulatory changes it might undertake to address the issue, such as deploying least costly alternative (LCA) or inherent reasonableness authority. However, both of these paths face considerable legal and political obstacles, and LCA policies likely would require legislation restoring HHS authority prior to implementation.